Letter to the editor

摘要

Making a formulary decision entails piecing together a jigsaw puzzle, except it remains to be determined which pieces belong in the puzzle that are relevant for the picture to be elucidated. The CER (Comparative Effectiveness Research) Collaborative toolkit comes into use in this respect by providing a systematic framework to analyze the quality of the evidence and its applicability to a health plan. In our case study for Eylea (aflibercept), we found the toolkit to be valuable in guiding evidence-based team discussion. Since we employed a broad range of resources, the study assessments proved particularly useful for evaluating relevance and credibility. For example, the trials for the CRVO (central retinal vein occlusion) indication only compared aflibercept with placebo; hence, we deemed it critical to objectively judge the strength of evidence of a meta-analysis comparing different CRVO treatments.